´ëÇѵÎÅëÇÐȸ 2023Ãá°èÇмú´ëȸ : 2023-06-25
±³À°ÀÏÀÚ : 2023-06-25
±³À°Àå¼Ò : ¼¿ïµå·¡°ï½ÃƼȣÅÚ ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ
±³À°ÁÖÁ¦ : ´ëÇѵÎÅëÇÐȸ 2023Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѵÎÅëÇÐȸ
´ã´çÀÚ : ÀåÁ¤¹®
¿¬¶ôó : 02-6411-7331
À̸ÞÀÏ : khs.secretariat@innon.co.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, ½Å°æ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, °¡Á¤ÀÇÇаú, ÀÀ±ÞÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀÎ : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 9 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í <»çÀüµî·Ï>Æò»ýȸ¿ø¹×2022¿¬È¸ºñ³³ºÎÁ¤È¸¿ø40,000¿ø,¹Ì³³Á¤È¸¿ø70,000¿ø,ÁØȸ¿ø(Àü°øÀǹױâŸȸ¿ø,±ºÀÇ°ü,°øº¸ÀÇ)40,000¿ø,ºñȸ¿ø70,000¿ø <ÇöÀåµî·Ï>Æò»ýȸ¿ø¹×2022¿¬È¸ºñ³³ºÎÁ¤È¸¿ø50,000¿ø,¹Ì³³Á¤È¸¿ø80,000¿ø,ÁØȸ¿ø(Àü°øÀǹױâŸȸ¿ø,±ºÀÇ°ü,°øº¸ÀÇ)50,000¿ø,ºñȸ¿ø80,000¿ø <¿öÅ©¼¥-¼±Âø¼ø> 40,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:10~09:30 Reversible cerebral vasoconstriction syndrome ¹ÚÈ«±Õ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:30~09:50 Pediatric migraine ³ªÁöÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 09:50~10:10 Other primary headaches ±è¼ö°æ(°æ»óÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:10~10:30 Headache attributed to disorder of homoeostasis Á¶¼öÇö(À»ÁöÀÇ´ë)
Åä·Ð 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:30~10:40 Q & A -(-)
ÈÞ½Ä 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:40~10:50 Coffee Break -(-)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 10:50~11:06 (±¸¿¬¹ßÇ¥:A ROOM)Treatment outcome of switching between monoclonal antibodies targeting calcitonin gene-related peptide in patients with migraine À±¼ÒÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:06~11:22 (±¸¿¬¹ßÇ¥:A ROOM)External validation of the Bern score for diagnosing spontaneous intracranial hypotension ÃÖ¼Ò¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:22~11:38 (±¸¿¬¹ßÇ¥:A ROOM)A Nationwide Cohort Study on the Association Between Migraine and Parkinson Disease ÇÏ¿ì¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:38~11:54 (±¸¿¬¹ßÇ¥:A ROOM)Changes in frequency and severity of neck pain after the treatment for medication-overuse headache Á¶¼öÁø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 11:54~12:10 (±¸¿¬¹ßÇ¥:A ROOM)Effect of body weight on the risk of migraine: a nationwide cohort study ±è³²¿À(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 10:50~11:10 (±¸¿¬¹ßÇ¥:B ROOM)Medication-overuse headache treatment and responsiveness to acute medications °¹Ì°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:10~11:30 (±¸¿¬¹ßÇ¥:B ROOM)Effect of smoking on the development of migraine in women: a nationwide cohort study ±è½Â¾Ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:30~11:50 (±¸¿¬¹ßÇ¥:B ROOM)Evaluation of Trigger Factors for Pediatric Migraine: A Single-Center Study ¼ÕÇýÁØ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ½Å¶óȦ 1+2+3 11:50~12:10 (±¸¿¬¹ßÇ¥:B ROOM)Disease course and predictors of recurrence in patients with cluster headache: a prospective follow-up study À̹ÌÁö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 12:10~12:30 Current evidence and practical suggestions for CGRP antagonist ¹®Èñ¼ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 12:30~12:50 How to maintain, stop, and troubleshoot CGRP monoclonal antibodies? ±èº´¼ö(ÀÌÈÀÇ´ë)
Åä·Ð 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 12:50~13:10 Panel Discussion -(-)
ÈÞ½Ä 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:10~13:30 µÎÅëÇÐȸÁö ÃÖ¿ì¼ö/¿ì¼ö³í¹®»ó ½Ã»ó½Ä -(-)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:30~13:50 Pitfalls of diagnosing pressure-related headaches ±èÁö¿µ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 13:50~14:10 Management of idiopathic intracranial hypertension ÃÖÀçȯ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:10~14:30 Management of spontaneous intracranial hypotension À̹ÌÁö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:30~14:50 Interventional approach of spontaneous intracranial hypotension ÀÌ¿µÁØ(¼¿ïÀÇ´ë)
Åä·Ð 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 14:50~15:00 Q & A -(-)
ÈÞ½Ä 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 15:00~15:10 Coffee Break -(-)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 15:10~15:50 Advances in the genetics of migraine Gisela M. Terwindt(Leiden University Medical Centre (LUMC), Netherlands)
Åä·Ð 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 15:50~16:00 Q & A -(-)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 16:10~16:55 Nerve blocks in headache ¹è´ë¿õ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 25ÀÏ ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ, ÄÁº¥¼ÇŸ¿ö 3F ±×·£µåº¼·ë ÇѶóȦ 16:55~17:40 Botulinum toxin injection in chronic migraine ¼Á¾±Ù(°æºÏÀÇ´ë)